Wedbush Analysts Lift Earnings Estimates for Geron

Geron Co. (NASDAQ:GERN) – Wedbush lifted their Q2 2025 earnings per share estimates for Geron in a report released on Wednesday, May 7th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will post earnings of ($0.02) per share for the quarter, up from their previous estimate of ($0.03). The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron’s Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.08) EPS.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $39.60 million during the quarter, compared to analysts’ expectations of $49.88 million. During the same period in the previous year, the business earned ($0.07) earnings per share. The firm’s revenue for the quarter was up 12927.3% on a year-over-year basis.

Several other analysts have also recently commented on GERN. Stifel Nicolaus dropped their price target on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Barclays restated an “overweight” rating and issued a $4.00 target price (down from $9.00) on shares of Geron in a report on Thursday, February 27th. B. Riley cut Geron from a “buy” rating to a “neutral” rating and dropped their target price for the company from $3.50 to $2.00 in a report on Thursday, February 27th. HC Wainwright restated a “neutral” rating on shares of Geron in a report on Wednesday, March 12th. Finally, Needham & Company LLC restated a “buy” rating and issued a $5.00 target price on shares of Geron in a report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.06.

Geron Stock Down 6.3%

Shares of GERN opened at $1.20 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a one year low of $1.17 and a one year high of $5.34. The stock has a market capitalization of $764.30 million, a price-to-earnings ratio of -3.75 and a beta of 0.76. The stock has a 50 day moving average price of $1.47 and a 200 day moving average price of $2.69.

Hedge Funds Weigh In On Geron

Several large investors have recently modified their holdings of GERN. Vestal Point Capital LP lifted its stake in shares of Geron by 947.6% in the 4th quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock valued at $38,940,000 after purchasing an additional 9,950,000 shares during the last quarter. Braidwell LP acquired a new position in shares of Geron in the 4th quarter valued at $24,802,000. Boxer Capital Management LLC acquired a new position in shares of Geron in the 4th quarter valued at $21,240,000. Woodline Partners LP lifted its stake in shares of Geron by 64.6% in the 4th quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company’s stock valued at $41,019,000 after purchasing an additional 4,549,031 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Geron by 20.0% in the 4th quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company’s stock valued at $95,769,000 after purchasing an additional 4,516,615 shares during the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.